Early Dual versus Mono Antiplatelet Therapy for Acute Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack: An Updated Systematic Review and Meta-Analysis
Clinical Trials Tuesday, September 17th, 2013CIRCULATIONAHA: September 12, 2013
Background—Emerging studies suggest that early administration of dual antiplatelet therapy may be better than monotherapy for prevention of early recurrent stroke and cardiovascular outcomes in acute ischemic stroke (IS) and transient ischemic attack (TIA). We performed a meta-analysis of randomized controlled trials (RCTs) evaluating dual versus mono antiplatelet therapy for acute non-cardioembolic IS or TIA.
Methods and Results—We assessed RCTs investigating dual versus mono antiplatelet therapy published up to November 2012 and the CHANCE trial (Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events), for efficacy and safety outcomes in adult patients with acute non-cardioembolic IS or TIA with treatment initiated within 3 days of ictus. Read more
